Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells.
O'Brien E, Tse C, Tracy I, Reddin I, Selfe J, Gibson J, Tapper W, Pengelly RJ, Gao J, Aladowicz E, Petts G, Thway K, Popov S, Kelsey A, Underwood TJ, Shipley J, Walters ZS. O'Brien E, et al. Among authors: underwood tj. Clin Epigenetics. 2023 Oct 19;15(1):167. doi: 10.1186/s13148-023-01583-w. Clin Epigenetics. 2023. PMID: 37858275 Free PMC article.
Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma.
Izadi F, Sharpe BP, Breininger SP, Secrier M, Gibson J, Walker RC, Rahman S, Devonshire G, Lloyd MA, Walters ZS, Fitzgerald RC, Rose-Zerilli MJJ, Underwood TJ, On Behalf Of Occams. Izadi F, et al. Among authors: underwood tj. Cancers (Basel). 2021 Jul 6;13(14):3394. doi: 10.3390/cancers13143394. Cancers (Basel). 2021. PMID: 34298611 Free PMC article.
Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts.
Sharpe BP, Hayden A, Manousopoulou A, Cowie A, Walker RC, Harrington J, Izadi F, Breininger SP, Gibson J, Pickering O, Jaynes E, Kyle E, Saunders JH, Parsons SL, Ritchie AA, Clarke PA, Collier P, Mongan NP, Bates DO, Yacqub-Usman K, Garbis SD, Walters Z, Rose-Zerilli M, Grabowska AM, Underwood TJ. Sharpe BP, et al. Among authors: underwood tj. Cell Rep Med. 2022 Jun 21;3(6):100541. doi: 10.1016/j.xcrm.2022.100541. Cell Rep Med. 2022. PMID: 35732148 Free PMC article.
Review: Targeting EZH2 in neuroblastoma.
Gao J, Fosbrook C, Gibson J, Underwood TJ, Gray JC, Walters ZS. Gao J, et al. Among authors: underwood tj. Cancer Treat Rev. 2023 Sep;119:102600. doi: 10.1016/j.ctrv.2023.102600. Epub 2023 Jul 13. Cancer Treat Rev. 2023. PMID: 37467626 Free article. Review.
Residual cancer cells after apparent complete pathological response to neoadjuvant therapy in oesophageal adenocarcinoma.
Walker RC, Harrington J, Breininger SP, Pickering O, Hill SL, Sharpe BP, Grace B, Reddin I, Rajak R, Manousopoulou A, Garbis SD, Walters ZS, Rose-Zerilli MJJ, Underwood TJ. Walker RC, et al. Among authors: underwood tj. Br J Surg. 2024 Apr 3;111(4):znae103. doi: 10.1093/bjs/znae103. Br J Surg. 2024. PMID: 38630793 Free PMC article. No abstract available.
ELEVATE - evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial.
Smyth E, Cozens K, Griffiths D, Clark KL, Ewings S, Petty R, Underwood T, Fitzgerald RC, Tanner J, Giger O, Anand S, Griffiths G. Smyth E, et al. BMC Cancer. 2022 Sep 1;22(1):946. doi: 10.1186/s12885-022-09891-9. BMC Cancer. 2022. PMID: 36050653 Free PMC article.
148 results